Neurocrine wins FDA approval for ‘sprinkle’ formulation of Ingrezza for Huntington’s disease
Neurocrine Biosciences won the FDA’s approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route of treatment for Huntington’s disease patients with trouble swallowing.